Kymera Therapeutics GAAP EPS of -$0.97 misses by $0.18, revenue of $2.9M misses by $11.9M
Source: SeekingAlpha
2026-02-26 07:18:13 ET
More on Kymera Therapeutics
- Kymera Therapeutics: The More This Biotech Spends, The Higher Its Valuation Rises
- Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Kymera Therapeutics Q4 2025 Earnings Preview
- Kymera Therapeutics prices $602M public offering at $86.00 a share
Read the full article on Seeking Alpha
For further details see:
Kymera Therapeutics GAAP EPS of -$0.97 misses by $0.18, revenue of $2.9M misses by $11.9M
Kymera Therapeutics Inc.
NASDAQ: KYMR
KYMR Trading
2.71% G/L:
$86.34 Last:
117,455 Volume:
$84.86 Open:
KYMR Latest News
March 10, 2026 07:00:00 am
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
February 26, 2026 07:00:00 am
Kymera Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
KYMR Stock Data
$6,259,529,627
60,213,376
0.01%
74
N/A
Biotechnology & Life Sciences
Healthcare
US
Watertown
